Inquiry Basket
Loading ......
Filter By Product Search for
BCAS2
BCAS2 Full Name
breast carcinoma amplified sequence 2
BCAS2 Introduction
BCAS2 (breast carcinoma amplified sequence 2), also known as pre-mRNA-splicing factor SPF27, is a conserved nuclear protein best known as a component of the PRP19-associated spliceosomal complex. For researchers studying cancer biology, developmental disorders, or RNA processing, BCAS2 is particularly relevant because it connects pre-mRNA splicing with cell survival, proliferation, and genome maintenance. Rather than acting as a classical signaling receptor or enzyme, BCAS2 helps maintain accurate RNA maturation by participating in spliceosome-associated complexes, including interactions with CDC5L and PRP19. Experimental studies have shown that disrupting BCAS2 can produce widespread alternative-splicing abnormalities, making it a useful molecular target for investigating how defective RNA processing contributes to cellular dysfunction.
BCAS2 has also emerged as an important regulator of cell-cycle progression, DNA damage responses, and tissue development. Studies in reproductive and hematopoietic models indicate that BCAS2-dependent splicing is required for the survival and proper differentiation of specialized cell populations. In mouse oocytes, conditional loss of Bcas2 causes extensive changes in alternative-splicing events and disrupts genes involved in oogenesis, meiotic progression, and spindle assembly. In granulosa cells, BCAS2 deficiency has been associated with abnormal E2f3 and Flt3l mRNA splicing, reduced proliferation, cell-cycle arrest, DNA damage, and apoptosis. Similarly, evidence from hematopoietic development suggests that loss of BCAS2 can disturb Mdm4 splicing, resulting in inappropriate p53 activation and depletion of hematopoietic stem and progenitor cells. These findings highlight a key biological principle: BCAS2 is not simply a splicing-associated protein, but a potential coordinator between RNA processing and cellular stress responses.
From a disease perspective, BCAS2 is attracting attention in cancer research because altered BCAS2 expression and function may support malignant cell survival and genome stability. In prostate cancer, BCAS2 has been reported to be enriched in advanced tumors and to interact with NBS1, enhancing DNA double-strand break repair through both homologous recombination and non-homologous end joining. Higher BCAS2 expression has also been associated with unfavorable pathological features, including higher Gleason grade and shorter survival, suggesting potential value as a cancer biomarker or mechanistic target. However, BCAS2 biology remains context-dependent, and its therapeutic relevance requires careful validation because its essential roles in normal cell proliferation, development, and RNA splicing may create a narrow therapeutic window. For researchers evaluating BCAS2 as a target, examining expression levels together with alternative-splicing patterns, DNA repair activity, cell-cycle phenotypes, and disease-specific genetic context can provide a more informative assessment than measuring BCAS2 abundance alone.
Alternate Names for BCAS2
BCAS2; breast carcinoma amplified sequence 2; pre-mRNA-splicing factor SPF27; DAM1; Snt309; SPF27; breast carcinoma-amplified sequence 2; spliceosome-associated protein SPF 27; DNA amplified in mammary carcinoma 1 protein; spliceosome associated protein, amplified in breast cancer;
Loading ......
